Citadel Advisors’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-36,100
| Closed | -$220K | – | 15473 |
|
|
2021
Q3 | $220K | Buy |
36,100
+500
| +1% | +$3.12K | ﹤0.01% | 11795 |
|
|
2021
Q2 | $293K | Buy |
35,600
+6,200
| +21% | +$52.7K | ﹤0.01% | 11332 |
|
|
2021
Q1 | $263K | Sell |
29,400
-17,000
| -37% | -$195K | ﹤0.01% | 11141 |
|
|
2020
Q4 | $535K | Buy |
46,400
+11,100
| +31% | +$129K | ﹤0.01% | 8022 |
|
|
2020
Q3 | $367K | Sell |
35,300
-39,400
| -53% | -$483K | ﹤0.01% | 7798 |
|
|
2020
Q2 | $982K | Buy |
74,700
+44,600
| +148% | +$462K | ﹤0.01% | 5864 |
|
|
2020
Q1 | $237K | Sell |
30,100
-3,900
| -11% | -$58.7K | ﹤0.01% | 7727 |
|
|
2019
Q4 | $704K | Buy |
34,000
+16,800
| +98% | +$283K | ﹤0.01% | 6227 |
|
|
2019
Q3 | $236K | Buy |
17,200
+2,600
| +18% | +$30.9K | ﹤0.01% | 7931 |
|
|
2019
Q2 | $180K | Buy |
14,600
+2,500
| +21% | +$28.8K | ﹤0.01% | 8264 |
|
|
2019
Q1 | $151K | Sell |
12,100
-6,100
| -34% | -$81.5K | ﹤0.01% | 8382 |
|
|
2018
Q4 | $206K | Sell |
18,200
-200
| -1% | -$3.14K | ﹤0.01% | 7823 |
|
|
2018
Q3 | $344K | Buy |
18,400
+600
| +3% | +$13.8K | ﹤0.01% | 7350 |
|
|
2018
Q2 | $460K | Buy |
17,800
+900
| +5% | +$23.4K | ﹤0.01% | 6510 |
|
|
2018
Q1 | $379K | Sell |
16,900
-3,600
| -18% | -$87.9K | ﹤0.01% | 6360 |
|
|
2017
Q4 | $513K | Buy |
20,500
+3,600
| +21% | +$88.2K | ﹤0.01% | 5612 |
|
|
2017
Q3 | $409K | Sell |
16,900
-1,200
| -7% | -$28.2K | ﹤0.01% | 5603 |
|
|
2017
Q2 | $366K | Sell |
18,100
-23,000
| -56% | -$479K | ﹤0.01% | 5576 |
|
|
2017
Q1 | $1.11M | Buy |
41,100
+27,600
| +204% | +$563K | ﹤0.01% | 3855 |
|
|
2016
Q4 | $257K | Buy |
+13,500
| New | +$258K | ﹤0.01% | 5900 |
|
|
2016
Q2 | – | Sell |
-10,700
| Closed | -$98K | – | 7620 |
|
|
2016
Q1 | $98K | Sell |
10,700
-4,000
| -27% | -$48.5K | ﹤0.01% | 6037 |
|
|
2015
Q4 | $283K | Buy |
+14,700
| New | +$255K | ﹤0.01% | 5297 |
|
Citadel Advisors's FLXN Position: Q4 2021 in Review
Citadel Advisors sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 266,575 shares — an estimated $1.63M sold.
Citadel Advisors first reported a position in FLXN in Q2 2015 and held it in 18 quarters. The position peaked at $5.55M in Q4 2019. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Citadel Advisors reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 266,575 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $1.63M.
- Citadel Advisors first reported a position in Flexion Therapeutics, Inc. in Q2 2015 and held it in 18 quarters.
- Citadel Advisors's Flexion Therapeutics, Inc. position peaked at $5.55M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.